172 related articles for article (PubMed ID: 26496308)
1. Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.
Isaka T; Yokose T; Ito H; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Nakayama H; Masuda M
Medicine (Baltimore); 2015 Oct; 94(42):e1784. PubMed ID: 26496308
[TBL] [Abstract][Full Text] [Related]
2. Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer.
Jin Y; Chen M; Yu X
Sci Rep; 2016 Aug; 6():31636. PubMed ID: 27527915
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma.
Isaka T; Nakayama H; Yokose T; Ito H; Miyagi Y; Matsuzaki T; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Masuda M
Ann Thorac Surg; 2016 Dec; 102(6):1821-1828. PubMed ID: 27553497
[TBL] [Abstract][Full Text] [Related]
5. Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR.
Isaka T; Yokose T; Ito H; Nakayama H; Miyagi Y; Saito H; Masuda M
BMC Pulm Med; 2021 Mar; 21(1):100. PubMed ID: 33757469
[TBL] [Abstract][Full Text] [Related]
6. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
Motoi N; Szoke J; Riely GJ; Seshan VE; Kris MG; Rusch VW; Gerald WL; Travis WD
Am J Surg Pathol; 2008 Jun; 32(6):810-27. PubMed ID: 18391747
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between EGFR Mutations and Pathological Classification and
Specimen of Lung Adenocarcinoma].
Kang L; Zheng J; Zhu X
Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
[TBL] [Abstract][Full Text] [Related]
10. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
11. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation.
Chantranuwat C; Sriuranpong V; Huapai N; Chalermchai T; Leungtaweeboon K; Voravud N; Mutirangura A
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S322-9. PubMed ID: 16623049
[TBL] [Abstract][Full Text] [Related]
13. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
14. Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma.
Togashi Y; Masago K; Kubo T; Fujimoto D; Sakamori Y; Nagai H; Kim YH; Togashi K; Mishima M
Med Oncol; 2012 Dec; 29(5):3169-75. PubMed ID: 22492281
[TBL] [Abstract][Full Text] [Related]
15. [Correlation between the new lung adenocarcinoma classification and epidermal growth factor receptor mutation].
Zhang XD; Liu DR
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Aug; 50(4):640-644. PubMed ID: 30122764
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification.
Boukansa S; Benbrahim Z; Gamrani S; Bardai S; Bouguenouch L; Mazti A; Boutahiri N; Serraj M; Amara B; Ouadnouni Y; Smahi M; Alami B; Mellas N; El Fatemi H
Cancer Control; 2022; 29():10732748221084930. PubMed ID: 35348028
[TBL] [Abstract][Full Text] [Related]
17. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
[No Abstract] [Full Text] [Related]
18. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
[TBL] [Abstract][Full Text] [Related]
19. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
20. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
